Advertisement

Topics

Latest "Biosciences" News Stories

17:31 EDT 23rd April 2018 | BioPortfolio

Here are the most relevant search results for "Biosciences" found in our extensive news archives from over 250 global news sources.

More Information about Biosciences on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biosciences for you to read. Along with our medical data and news we also list Biosciences Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biosciences Companies for you to search.

Showing "Biosciences" News Articles 1–25 of 1,000+

Relevant

ASC Biosciences, Inc. announces ad dates for first television commercial

About ASC Biosciences, Inc.ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company with a proprietary adult stem cell platform capable Read more...


SOLID BIOSCIENCES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Solid Biosciences Inc. to Contact The Firm

NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Solid Biosciences Inc. ("Solid Biosciences" or th...

Kuros Biosciences Ltd.: Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus

Schlieren (Zürich), Schweiz, 8. Januar 2018 Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus Kuros Biosciences AG (SIX: KURN) gibt die Ausdehnung des exklusiven Lizenzabkommens mit Checkm...


Apricus Biosciences, Inc.: Apricus Biosciences Announces Proposed Public Offering

SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that ...

Apricus Biosciences, Inc.: Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative me...

Kuros Biosciences Ltd.: Kuros Biosciences sichert mögliche Eigenkapitalfinanzierung von bis zu CHF 30 Millionen

Schlieren (Zürich), Schweiz, 22. November 2017 Kuros Biosciences sichert mögliche Eigenkapitalfinanzierung von bis zu CHF 30 Millionen Kuros Biosciences (SIX: KURN) gibt den Abschluss eines Standb...

Kuros Biosciences Ltd.: Kuros Biosciences gibt Nachfolge im Management bekannt

Schlieren (Zürich), Schweiz, 14. Dezember 2017 Kuros Biosciences gibt Nachfolge im Management bekannt Kuros Biosciences AG (SIX: KURN) gibt die Ernennung von Michael Grau zum Chief Financial Offic...

AB Biosciences & Shire Enter License Agreement

For AB Biosciences' pan receptor interacting molecule (PRIM) program

Shire plc: AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program

AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program for Potential Treatment of Autoimmune Diseases and Other Immune-Mediated Disorde...

Head to Head Survey: DARA Biosciences

DARA Biosciences and Mallinckrodt PLC are both specialty & advanced pharmaceuticals companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings. DARA Biosciences has a beta of 0.72, indicating that its share price is 28% less volatile t...

Kuros Biosciences Ltd.: Chief Medical Officer von Kuros Biosciences geht in Pension

Chief Medical Officer von Kuros Biosciences geht in Pension Schlieren (Zürich), Schweiz, 28. November 2017 - Kuros Biosciences AG (SIX: KURN) gibt heute bekannt, dass ihr Chief Medical Officer, Dr...

Shire to develop AB Biosciences’ platform for autoimmune diseases

Shire has obtained exclusive worldwide licence for the development and commercialisation of US-based AB Biosciences’ pan receptor interacting molecule (PRIM)...Read More... The post Shire to develop AB Biosciences’ platform for autoimmune diseases appeared first on Pharmaceutical Technology.

Pawar Law Group: Solid Biosciences Inc. Reminder: Important May 29, 2018 Lead Plaintiff Deadline in Class Action - SLDB

NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Pawar Law Group reminds shareholders who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB): (1) in Solid Biosciences' initial public offering on...

Solid Biosciences to study SGT-001 in Phase I/II DMD trial

US-based Solid Biosciences has launched a Phase I/II (IGNITE DMD) clinical trial of its microdystrophin gene transfer candidate SGT-001 in...Read More... The post Solid Biosciences to study SGT-001 in Phase I/II DMD trial appeared first on Drug Development Technology.

#news #biotech Arcus Biosciences eyes $100M IPO

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Arcus Biosciences eyes $100M IPO .Mere months after bagging $107 million in its series C round, Arcus Biosciences is teeing up for a $100 million IPO, which will … Continue reading → Cet article #news #biotech Arcus Biosciences eyes $100M IPO est apparu en premier ...

Solid Biosciences hit hard by study stoppage

Duchenne’s muscular dystrophy (DMD) specialist Solid Biosciences has been told by the US Food and…

Armo BioSciences files for its IPO

Immuno-oncology firm Armo BioSciences Inc. has filed for its initial public offering.

SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against Solid Biosciences, Inc. -- SLDB

RADNOR, PA / ACCESSWIRE / March 30, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts Solid Biosciences, Inc. (NASDAQ: SLDB) ("Solid Biosciences" or the "Company") shareholders that ...

Arcus Biosciences files for IPO

Arcus Biosciences Inc. (cancer immunotherapies) filed for its initial public offering.

In The Spotlight: Catalyst Biosciences

Shares of Catalyst Biosciences Inc. (CBIO) are up an impressive 100% year-to-date in sharp contrast to the NASDAQ Biotechnology Index, which is down nearly 2% during the same period.

Evelo Biosciences files for IPO

Evelo Biosciences Inc. (therapeutics for inflammatory diseases and cancer based on the gut-body network) filed for an initial...

#jobs #lifescience Inflection Biosciences: Project Manager

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Inflection Biosciences: Project Manager . Dependent on experience: Inflection Biosciences: The person will have experience as a project manager for drug development programs in an outsourced setting. Dublin, … Continue reading → Cet article #jobs #lifescience Infle...

Aptose Biosciences (APTO) vs. Arena Pharmaceuticals (ARNA) Head to Head Contrast

Aptose Biosciences and Arena Pharmaceuticals are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. This is a breakdown of recent ratings and target prices for Aptose Biosciences and Arena Pharmaceuticals, as pr...

BRIEF—Dyve Biosciences launches as dermal delivery technology company

Dyve Biosciences officially launched today as a new face in the biopharmaceutical space in Thousand Oaks,…

Achillion Pharmaceuticals (ACHN) & Selecta Biosciences (SELB) Critical Comparison

Achillion Pharmaceuticals and Selecta Biosciences are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Selecta Biosciences has lower revenue, but higher earnings than Achillion Pharmaceuticals.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks